

Consortium for Medical Marijuana **Clinical Outcomes Research** 

### **Objective**

• To determine the priorities for medical marijuana research from the perspective of multiple stakeholders including patients, clinicians, and industry representatives.

### Methods

- An anonymous survey was administered to attendees of the 2019 American Medical Marijuana Physicians Association annual meeting in Orlando, Florida.
- Surveys were completed on paper or smartphone via Qualtrics.
- The survey included questions on demographics and medical marijuana research priorities under the following broad categories: clinical conditions, safety issues, marijuana types, populations, and other.


### Results

- 46 participants (56.5% female, mean age = 51.6±14.1) responded to the survey.
- Majority were medical marijuana qualified physicians in Florida (56.5%), 30.5% other physician or clinician, and 21.7% medical marijuana patients.
- Top clinical conditions prioritized for research by this group were chronic pain  $(3.7\pm0.7)$ , cancer  $(3.5\pm0.8)$  and anxiety  $(3.4\pm0.8)$  (Figure 1).
- Top priority safety issues were dosing/product choice  $(3.7\pm0.5)$ , complications from smoking/vaping  $(3.6\pm0.7)$ , and drug interactions  $(3.5\pm0.6)$  (Figure 2).
- Top priority for marijuana types were research on THC/CBD ratios  $(3.5\pm0.7)$ , different modes of consumption  $(3.4\pm0.7)$ , and terpenes  $(3.4\pm0.7)$ (Figure 3).
- Research topics under population were all perceived as important.

Dosing and/or medical marijuana... Complications from smoking or... Drug interactions with prescription... Research on marijuana and driving Schizophrenia and/or psychosis Simultaneous use with alcohol or ... Falls, balance problems Potential for addiction (cannabis use... Cyclic vomiting syndrome

# 

## **Priorities for Medical Marijuana Research from the** Perspective of physicians, Dispensary Owners/staff, and Patients: A Survey Study






Figure 2: Safety issues



Figure 3: Marijuana types

Medical marijuana stakeholders perceived a broad range in research topics as priorities.

The top priority conditions were chronic pain, cancer, and anxiety.

The top priority safety issues were dosing/product choice, complications from smoking/vaping, and drug interactions.

The top priority marijuana types were different THC/CBD ratios, different modes of consumption, and terpenes.

Jennifer Jean-Jacques, MPH<sup>1</sup>; Robert Cook, MD, MPH<sup>1</sup>; Almut G Winterstein, RPh, PhD, FISPE<sup>1,2</sup>; Amie Goodin, PhD, MPP<sup>2</sup>; Joshua Brown, PharmD, PhD<sup>2</sup>; Sebastian Jugl, RPh<sup>2</sup>; Yan Wang, PhD<sup>1</sup>

#### Affiliations

1Department of Epidemiology, University of Florida, Gainesville, Florida, United States **2Department of Pharmaceutical Outcomes and** Policy, Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, United States



\* Contact corresponding author j.jeanjacques@ufl.edu



**Contact MMJ Outcomes** mmj.outcomes@cop.ufl.edu https://mmjoutcomes.org/